• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Affordability of Guideline-Directed Medical Therapy: Cost Sharing is a Critical Barrier to Therapy Adoption.

作者信息

Sandhu Alexander T, Heidenreich Paul A

机构信息

Division of Cardiology, Department of Medicine, Stanford University, CA (A.T.S., P.A.H.).

Medical Service, Veterans Affairs Palo Alto Health Care System, CA (P.A.H.).

出版信息

Circulation. 2021 Mar 16;143(11):1073-1075. doi: 10.1161/CIRCULATIONAHA.120.053291. Epub 2021 Mar 15.

DOI:10.1161/CIRCULATIONAHA.120.053291
PMID:33720777
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8100979/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a57f/8100979/1d75b6ff1973/nihms-1671616-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a57f/8100979/1d75b6ff1973/nihms-1671616-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a57f/8100979/1d75b6ff1973/nihms-1671616-f0001.jpg

相似文献

1
The Affordability of Guideline-Directed Medical Therapy: Cost Sharing is a Critical Barrier to Therapy Adoption.指南指导的药物治疗的可负担性：费用分摊是治疗采用的关键障碍。
Circulation. 2021 Mar 16;143(11):1073-1075. doi: 10.1161/CIRCULATIONAHA.120.053291. Epub 2021 Mar 15.
2
Cost Sharing, Health Care Expenditures, and Utilization: An International Comparison.成本分担、医疗保健支出与利用：一项国际比较
Int J Health Serv. 2016;46(1):106-23. doi: 10.1177/0020731415615312. Epub 2015 Nov 6.
3
Specialty drug coupons lower out-of-pocket costs and may improve adherence at the risk of increasing premiums.特药优惠券降低了自付费用，并可能提高了患者的用药依从性，但却增加了保费。
Health Aff (Millwood). 2014 Oct;33(10):1761-9. doi: 10.1377/hlthaff.2014.0497.
4
Power of 1 Malaysian Ringgit: A Low-Cost Prescription Cost-Sharing Model in Malaysia.1 令吉的力量：马来西亚的低成本共付处方药模式。
Value Health Reg Issues. 2020 May;21:245-251. doi: 10.1016/j.vhri.2019.12.002. Epub 2020 Apr 27.
5
The impact of pharmaceutical rebates on patients' drug expenditures.药品回扣对患者药品支出的影响。
CMAJ. 2019 Mar 18;191(11):E308-E312. doi: 10.1503/cmaj.181041.
6
Physician and Patient Adjustment to Reference Pricing for Drugs.医生和患者对药品参考定价的调整。
JAMA Netw Open. 2020 Feb 5;3(2):e1920544. doi: 10.1001/jamanetworkopen.2019.20544.
7
Systematic review of benefit designs with differential cost sharing for prescription drugs.对处方药采用差异化费用分担的福利设计的系统评价。
Am J Manag Care. 2015 May 1;21(5):e338-48.
8
Australia's pharmaceutical cost sharing policy: reducing waste or affordability?澳大利亚的药品费用分担政策：减少浪费还是提高可负担性？
Aust Health Rev. 2009 May;33(2):231-40. doi: 10.1071/ah090231.
9
The cost of admission--tiered copayments for hospital use.住院费用——针对医院使用的分级自付费用。
N Engl J Med. 2004 Jun 17;350(25):2539-42. doi: 10.1056/NEJMp048107.
10
Pharmaceutical Benefits Scheme cost sharing, patient cost consciousness and prescription affordability.药品福利计划成本分摊、患者成本意识与处方可负担性。
Aust Health Rev. 2011 Feb;35(1):37-44. doi: 10.1071/AH10902.

引用本文的文献

1
From Metabolic Syndrome to Cardiovascular-Kidney-Metabolic Syndrome and Systemic Metabolic Disorder: A Call to Recognize the Progressive Multisystemic Dysfunction.从代谢综合征到心血管-肾脏-代谢综合征及全身性代谢紊乱：呼吁认识渐进性多系统功能障碍
Anatol J Cardiol. 2025 Aug;29(8):384-393. doi: 10.14744/AnatolJCardiol.2025.5602.
2
Sodium-Glucose Cotransporter 2 Inhibitor Use for Heart Failure in US Ambulatory Cardiovascular Care.钠-葡萄糖协同转运蛋白2抑制剂在美国门诊心血管护理中用于治疗心力衰竭。
JAMA Cardiol. 2025 Jul 9. doi: 10.1001/jamacardio.2025.2145.
3
Challenges Related to Out-of-Pocket Costs in Heart Failure Management.

本文引用的文献

1
Eliminating medication copayments reduces disparities in cardiovascular care.消除药物自付费用可减少心血管护理方面的差异。
Health Aff (Millwood). 2014 May;33(5):863-70. doi: 10.1377/hlthaff.2013.0654.
2
Prescription drug cost sharing: associations with medication and medical utilization and spending and health.处方药费用分担：与药物使用、医疗利用、支出及健康的关联
JAMA. 2007 Jul 4;298(1):61-9. doi: 10.1001/jama.298.1.61.
心力衰竭管理中与自付费用相关的挑战
Circ Heart Fail. 2025 Mar;18(3):e011584. doi: 10.1161/CIRCHEARTFAILURE.124.011584. Epub 2025 Feb 28.
4
Social Determinants of Health and Disparities in Guideline-Directed Medical Therapy Optimization for Heart Failure.心力衰竭指南指导下药物治疗优化中的健康社会决定因素与差异
Circ Heart Fail. 2025 Jan;18(1):e012357. doi: 10.1161/CIRCHEARTFAILURE.124.012357. Epub 2024 Nov 11.
5
Health insurance and clinical outcomes in patients with chronic heart failure in Latin America: an observational study of the Colombian Heart Failure Registry (RECOLFACA).拉丁美洲慢性心力衰竭患者的医疗保险与临床结局：哥伦比亚心力衰竭注册研究（RECOLFACA）的观察性研究。
Heart Vessels. 2024 Dec;39(12):1068-1078. doi: 10.1007/s00380-024-02456-9. Epub 2024 Sep 12.
6
Medical Management and Device-Based Therapies in Chronic Heart Failure.慢性心力衰竭的药物治疗与基于器械的疗法
J Soc Cardiovasc Angiogr Interv. 2023 Dec 4;2(6Part B):101206. doi: 10.1016/j.jscai.2023.101206. eCollection 2023 Nov-Dec.
7
The economics of heart failure care.心力衰竭治疗的经济学。
Prog Cardiovasc Dis. 2024 Jan-Feb;82:90-101. doi: 10.1016/j.pcad.2024.01.010. Epub 2024 Jan 18.
8
Eliminating Health Disparities in Atrial Fibrillation, Heart Failure, and Dyslipidemia: A Path Toward Achieving Pharmacoequity.消除心房颤动、心力衰竭和血脂异常中的健康差异：实现药物平等的途径。
Curr Atheroscler Rep. 2023 Dec;25(12):1113-1127. doi: 10.1007/s11883-023-01180-5. Epub 2023 Dec 18.
9
Financial Toxicity of Medical Management of Heart Failure: JACC Review Topic of the Week.心力衰竭医学管理的经济毒性：JACC 本周综述主题。
J Am Coll Cardiol. 2023 May 23;81(20):2043-2055. doi: 10.1016/j.jacc.2023.03.402.
10
Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Risk Factors Under the Inflation Reduction Act.《平价医疗法案下，心血管疾病风险因素的 Medicare 受益人自付药品费用》。
J Am Coll Cardiol. 2023 Apr 18;81(15):1491-1501. doi: 10.1016/j.jacc.2023.02.002. Epub 2023 Feb 20.